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Abstract
Aims/hypothesis The aim of the present study was to
examine whether patients with diabetes in Scotland using
insulin glargine have a greater cancer risk than patients
using other types of insulin.
Methods We used a nationwide diabetes clinical database
that covers the majority of the Scottish population with
diagnosed diabetes, and examined patients with diabetes
who were exposed to any insulin therapy between 1 January
2002 and 31 December 2005. Among these we defined a
fixed cohort based on exposure during a 4 month period in
2003 (n=36,254, in whom 715 cases of cancer occurred) and
a cohort of new insulin users across the period (n=12,852 in
whom 381 cancers occurred). Records from these cohorts
were linked to cancer registry data up to the end of 2005. We
used Cox proportional hazards models for survival analyses.
Results Those receiving any insulin glargine (n=3,959) had
the same incidence rate for all cancers as those not
receiving insulin glargine (HR 1.02, 95% CI 0.77–1.36,
p=0.9 in the fixed cohort) The subset of patients using
insulin glargine alone (n=447) had a significantly higher
incidence of all cancers than those using other insulins only
(n=32,295) (HR 1.55, 95% CI 1.01–2.37, p=0.045), and
those using insulin glargine with other insulins (n=3,512)
had a slightly lower incidence (HR 0.81, 95% CI 0.55–
1.18, p=0.26). There were important differences in baseline
characteristics between these three groups, although the risk
ratios were broadly unaltered on adjustment for these.
Overall, there was no increase in breast cancer rates
associated with insulin glargine use (HR 1.49, 95% CI
0.79–2.83, though insulin glargine only users had a higher
rate than those using non-glargine insulin only (HR 3.39,
95% CI 1.46–7.85, p=0.004). Among type 2 diabetic
incident insulin users, no significant difference between
the three groups was observed with respect to all cancer or
breast cancer. All the above HRs are adjusted for age,
calendar time prior cancer and type of diabetes, as
appropriate, and are stratified according to sex.
Conclusions/interpretation Overall, insulin glargine use
was not associated with an increased risk of all cancers or
site-specific cancers in Scotland over a 4 year time frame.
Given the overall data, we consider the excess of cases of
all cancers and breast cancer in the subgroup of insulin
glargine only users to more likely reflect allocation bias
rather than an effect of insulin glargine itself.
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Introduction
Insulin glargine (A21Gly,B31Arg,B32Arg human insulin)
is a long-acting insulin analogue that is used as basal
insulin in people with diabetes and is given once daily. It is
produced by recombinant DNA technology and differs
from human insulin in that the amino acid asparagine at
position A21 is replaced by glycine, and two arginines are
added to the C-terminus of the B chain. This renders it less
soluble at physiological pH so that it has a prolonged action
such that serum concentrations are relatively constant over
a 24 h period [1].
Insulin glargine was first recommended for restricted use
in Scotland in October 2002 by the regulatory body, the
Scottish Medicines Consortium [2]. These guidelines
recommended that insulin glargine be used for patients
who had problems with nocturnal or recurrent hypoglycae-
mia or for once daily use in patients requiring carer
administration of their insulin. Routine use in patients with
type 2 diabetes was not recommended. This advice was
reiterated in 2008. In England and Wales, the National
Institute for Clinical Excellence (NICE) recommended
insulin glargine as a treatment option for type 1 diabetes
and recommended restricted use in type 2 diabetes, as in
Scotland, but with the added recommendation that it could
be used in type 2 diabetic patients who would otherwise
need twice daily basal insulin injections in combination
with oral glucose-lowering drugs [3]. These recommenda-
tions were updated by The National Collaborating Centre
for Chronic Conditions, commissioned by NICE, in 2008,
with the main change being a widening of the type 2
recommendations to allow consideration of insulin glargine
use in those who would otherwise need once daily basal
insulin injections in combination with oral glucose-lowering
drugs [4]. A recent implementation report from NICE
illustrates an annual increase in insulin glargine use since
2002, such that an estimated 42.6% of patients with type 1
diabetes and 4.4% with type 2 diabetes of patients received
a prescription for insulin glargine in the 12 months up to 31
March 2008 [5].
Since modifications to the structure of the insulin
molecule can alter binding to the insulin and IGF-1
receptors, this provides a theoretical basis for concern
about potential carcinogenicity of insulin analogues. Sys-
tematic reviews of the effects of insulin analogues on
glycaemic outcomes have identified the absence of trials of
sufficient duration to evaluate cancer rates [6] and have
concluded that more studies are needed to better understand
the effect of insulin analogues on long-term diabetes
complications and the safety of these agents [7].
Following the concerns raised by the paper by Hemkens
et al. [8] in this issue of Diabetologia we were asked by the
EASD to examine whether there was any evidence of an
association between cancer incidence and insulin glargine
use in Scotland. The Editor was aware that the Scottish
Diabetes Research Network (SDRN) Epidemiology Group
were preparing Scottish-wide data on diabetes care and
outcomes for research purposes including pharmacovigi-
lance. Scotland has a national register of patients with
diabetes, which includes prescribing data and has excellent
capacity for anonymised linkage to routine health data,
including cancer registry and mortality data [9]. The first
linkage was recently carried out by the Information and
Services Division (ISD) of NHS National Services Scotland
in a project funded by the Scottish Government. In view of
the lack of good quality evidence from randomised
controlled trials on this issue, we considered that such an
observational analysis was warranted.
Methods
Overview
We used the Scottish Care Information-Diabetes Collabo-
ration (SCI-DC), a clinical diabetes database that covers the
majority of the Scottish population with diagnosed diabetes,
to define a cohort of patients with diabetes who were
exposed to any insulin therapy from 1 January 2002 (the
year of introduction of insulin glargine) up until 31
December 2005. Data for all patients receiving an insulin
prescription during this period were extracted from the SCI-
DC database and linked to cancer registry data that were
available up to the end of 2005. The incidence of all
cancers and cancers at specific sites (breast, colon, prostate,
pancreas, lung) was compared between those who did and
did not receive insulin glargine.
Data used
SCI-DC Across Scotland, almost all adult patients with a
diagnosis of type 1 or type 2 diabetes are registered on the
SCI-DC database. The SCI-DC database has been available
Scotland-wide since 2000. The estimated coverage of the
total adult diabetic population is approximately 99%. This
database exists at Health Board level for all Health Boards
in Scotland, and each patient record contains a unique
identifier, the Community Health Index number. The
database captures key diabetes-related data items from
hospital clinics, most of which use SCI-DC as their main
clinical record system for diabetes. Some hospital clinics
use other systems, but these update key items in the SCI-
DC database. The database also receives updates of certain
data fields nightly from primary healthcare systems,
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including prescriptions that have been issued. The prescrib-
ing data available for this analysis were restricted to the
name of the drug prescribed and the date of prescription.
Data on dose and directions for use are not yet available. In
addition to data from the first date of a patient record into
the database onwards, it also contains extensive retrospec-
tive data uploaded from other electronic healthcare records
at the initial entry of a patient onto the database. The fields
extracted from SCI-DC for patients included in this analysis
included all prescribed diabetes-related drugs (British
National Formulary section 6.1.1 and 6.1.2, i.e. all insulin,
biguanides, sulfonylureas and other oral glucose-lowering
drugs), age, sex, BMI, age at diagnosis, type of diabetes as
designated by clinician, smoking history and Scottish Index
of Multiple Deprivation (SIMD) score derived from
postcode. The SIMD score is a geographic indicator of
deprivation that is based on 37 indicators across the
domains of current income, employment, health, education,
skills and training, housing, geographic access and crime
[10]. In the present study, quintiles of the SIMD score have
been used, with the lower quintile representing the most
deprived of our cohort. As of 2009, 219,965 live patients
with diabetes in Scotland are registered on this database.
For the purpose of these analyses, type of diabetes was
categorised as definite type 1 if age at diagnosis or use of
first insulin therapy was below 30 years, as definite type 2
if age at diagnosis and use of first drug treatment were
35 years or above, and indeterminate if age at diagnosis
was 30–35 years.
Cancer Register (Scottish Morbidity Record) The Scottish
Cancer Registry was set up in 1958 and has been managed
by the Information Services Division of NHS National
Services Scotland since 1997. The registry receives
notification of cancer from hospital systems, including
discharges, radiotherapy, oncology, haematology and
pathology records, prospective audit datasets, deaths from
the General Register Office for Scotland, and paper records
from private hospitals. Other staff verify the notification,
validate the information already held and abstract additional
information from hospital medical records and local
hospital systems before the data are finalised. Data quality
is monitored using routine indicators, computer validation,
ad hoc studies of data accuracy and completeness of
ascertainment, and through data exchange with specialist
registries. A recent study estimated that breast cancer
ascertainment exceeds 98% [11]. Of the data items
reported, we used the following in this analysis: date of
diagnosis, site of tumour and mortality. The International
Classification of Diseases, 9th and 10th revisions (ICD-9
and -10), were used to code the site of previous and
incident cancers. For this analysis, all non-melanoma skin
cancer tumours were captured; all C codes in ICD-10 codes
except non-melanoma skin cancer C44. Incident prostate
cancer was defined as ICD-10 code C61 and subcodes;
colorectal cancer was defined as ICD-10 codes C18, C19
and C20 and their subcodes; pancreatic cancer was defined
as ICD-10 code C25 and its subcodes. Breast cancer was
defined as ICD-10 code C50, and lung cancer was defined
as ICD-10 codes C33, C34 and their subcodes. There is
typically a lag time of about 2–3 years in availability of
validated data for research purposes, so data were only
available up to the end of 2005. The completeness and
accuracy of the Cancer Register data have been extensively
validated: recent estimates for accuracy and sensitivity for
breast cancer are 95.7% and 97.8%, respectively [12].
Deaths (General Registrar’s Office for Scotland-deaths)
All deaths that occur in Scotland are captured into the death
register of the General Registrar’s Office for Scotland
(GROS), on completion of a death certificate. For each
death, the GROS assigns a single code for the underlying
cause of death and, depending on what was written on the
death certificate, may assign several other codes for other
factors that contributed to death. The ICD-10 coding
system is used for data from 2000 onwards. For this
analysis, we extracted all death records when there was any
mention of cancer in the fields concerning underlying cause
of death and contributory cause of death.
Governance and ethics
As part of the core programme of work of the SDRN
Epidemiology Group, approval was obtained for anonymised
linkage of SCI-DC data to specified, centrally held health data
sets. Approval was obtained from the Scotland A Research
Ethics Committee, Caldicott Guardian for all 14 Health
Boards and the ISD Privacy Advisory Committee including
linkage to cancer registration data held at ISD.
Linkage methods
Linkage is carried out by ISD, and researchers only have
access to anonymised data. Two approaches to linkage were
used: exact linkage and probabilistic linkage. Exact linkage
was performed using the Community Health Index number,
which is noted on all SCI-DC records and most cancer
registry records but not GROS death records. When the
record did not have a Community Health Index number,
probabilistic linkage was performed using a selection of
identifiers common across datasets. In Scotland, both the
false-positive rate (the proportion of pairs that are incor-
rectly linked) and the false-negative rate (the proportion of
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pairs that the system fails to link) for this approach is less
than 3% [13].
Statistical methods
There are several possible ways to test the hypothesis of
an association between insulin glargine prescription and
cancer incidence in these observational data, each of
which can be subject to different biases. Thus, we
analysed the data in three ways, each of which potentially
yields different information. Our approach did not assume
any induction time and assumed that the effects, if any, of
exposure would continue beyond the exposure period.
Associations were declared as statistically significant if the
p value was <0.05. All analyses were performed using
STATA/MP version 10.0 for Unix (StataCorp, College
Station, TX, USA); using the Cox, stset and stsplit
procedures for survival analysis.
Fixed cohort analysis In this analysis we chose a 4 month
period between 1 July 2003 and 31 October 2003 during
which insulin glargine prescription was widespread and
reasonable follow-up time remained. All patients receiving
any type of insulin at any time over these 4 months were
entered into the analysis. Patients were defined as being
exposed to insulin glargine or not during this 4 month
period and were then followed up without regard to any
subsequent change in exposure status (akin to an intention-
to-treat analysis). By ignoring transition to other exposures,
this can minimise possible reverse causation bias in some
circumstances but can bias towards the null. We used Cox
proportional hazards models to examine our primary
hypothesis of whether the incidence of any cancer (and
cancer at specific sites) varied by exposure to insulin
glargine. As the analysis by Hemkens et al. [8] was
restricted to insulin glargine only users, we also examined
effects in insulin glargine only users and non-glargine plus
glargine insulin users separately. We used attained age as
the timescale of the model, and the entry time was 31
October 2003. The follow-up for each person was con-
tinued to the first of the following: date of first cancer
registration or cancer death, date of death from any cause,
or 31 December 2005. For analysis of specific types of
cancer, the right censoring event date was the date of the
first cancer of that type. For all analyses, confirmation that
the patient was still under observation within Scotland was
confirmed by the availability of other data items in the
database throughout the follow-up period (HbA1c, BMI, BP
and prescription records). We included type of diabetes,
calendar year and prior cancer as covariates (we also
confirmed that omitting those with prior cancer gave similar
results). We then extended these models by including
covariates that differed substantially between the exposure
categories at baseline, including BMI, systolic and diastolic
BP, smoking, glycaemic control, other concurrent diabetes
medications and socioeconomic status. We used models
that adjusted for type of diabetes and checked the effects in
models for each type of diabetes separately. For all models,
we confirmed that the assumption of proportional hazards
was not violated by testing for a non-zero slope in a
regression of scaled Schoenfeld residuals against time;
a non-zero slope is an indication of a violation of the
proportional hazards assumption. Individual tests by covariate
were performed, as well as a global test. As there was some
departure from proportionality of hazards by sex, the models
were stratified by sex.
Incident insulin cohort It could be argued that a caveat of
the fixed cohort approach above, especially in type 2
diabetic patients, is that observed differences between
exposure categories in the fixed cohort could reflect
differences between groups in the stage of progression of
their diabetes and prior treatments, for which we have
incomplete information. Therefore, we also undertook an
analysis among type 2 diabetes patients that was restricted
to those who starting insulin therapy for the first time
during follow-up from 1 January 2002 (the year insulin
glargine was first prescribed) to the end of 2005. In this
analysis, exposure was classified based on insulin treatment
in the first 4 months of use. The entry time to the cancer
incidence models was the end of the 4 month period (to
ensure that the period during which exposure is defined is
separate from the observation period). The follow-up for
each person was continued to the first of the following: date
of first cancer or cancer death, date of death from any
cause, or 31 December 2005. The timescale of the model
was attained age. The same covariate adjustments were
made as for the fixed cohort analysis.
Analysis with exposure classification across the follow-up
period The fixed cohort analysis described above is an
intention-to-treat analysis and ignores the reality that
patients transition between exposure categories. Therefore,
we also categorised patients on the basis of their exposure
across their entire follow-up period. In this analysis, those
on insulin glargine only never received insulin glargine
concomitantly with any other type of insulin, those on non-
glargine insulin only never had any insulin glargine at any
time during follow-up, and those on non-glargine plus
glargine insulin were using insulin glargine concomitantly
with another type of insulin for at least some of the time.
This analysis uses the data available more completely and
defines actual exposure more accurately but at the cost of
being more prone to reverse causation bias. As before, Cox
proportional hazards models were used, with entry time
being date of first insulin use.
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Results
All the HRs reported in the text below are adjusted for age
(since age was the timescale of the model), calendar time,
prior cancer and type of diabetes, as appropriate, and are
stratified by sex, unless stated otherwise.
Fixed cohort
Baseline characteristics A total of 36,254 people were
receiving any type of insulin therapy during the 4 month
exposure evaluation period (July to October 2003). There
were 3,959 people on insulin glargine; the majority (n=
3,512) were receiving insulin glargine with another insulin
and the remaining 447 patients were receiving insulin
glargine as their sole insulin. Table 1 shows the baseline
characteristics of those included in the fixed cohort analysis
according to insulin glargine exposure. There were signif-
icant and large differences in baseline characteristics across
the three exposure groups especially, of course, with respect
to the prevalence of type 1 diabetes. When these com-
parisons were restricted to the 19,899 insulin users with
definite type 2 diabetes (Table 2), compared with users of
non-glargine insulin alone, those on non-glargine plus
glargine insulin were younger, and values adjusted for age
and sex indicated that they had a lower BMI and less CVD,
but worse glycaemic control. For diabetes duration, the
non-glargine plus glargine insulin group had a lower
prevalence of diabetes duration at least 5 years, but,
adjusted for age, they had a higher prevalence (OR 1.38,
95% CI 1.25–1.52, p<0.0001). They also had a lower
prevalence of ever smoking and were less likely to be on
any concomitant oral therapy at baseline. Compared with
users of non-glargine insulin alone, insulin glargine only
users were older, had similar BMI but higher diastolic BP,
worse glycaemic control but shorter duration of diabetes,
and were much more likely to be on concomitant oral
therapy at baseline (Table 2).
Table 1 Baseline characteristics of the fixed cohort by insulin glargine exposure group (n=36,254)
Characteristic Non-glargine insulin Non-glargine plus
glargine insulin
Insulin glargine
only
p valuea
Subjects % (n) 89.1 (32,295) 9.7 (3,512) 1.2 (447)
Sex, % women % (n) 46.9 (15,153) 50.3 (1,765) 52.1 (233) <0.0001
Age, years median (LQ, UQ) 55 (38,68) 41 (30,54) 68 (58,76) <0.0001
BMI, kg/m2 mean (SD) 28.9 (6.2) 26.8 (5.0) 30.0 (6.3) <0.0001
Systolic BP, mmHg mean (SD) 135.0 (22.1) 130.1 (19.1) 139.8 (20.4) 0.58
Diastolic BP, mmHg mean (SD) 75.2 (11.9) 75.1 (11.0) 77.0 (12.6) 0.008
HbA1c, % mean (SD) 8.6 (1.7) 8.9 (1.6) 9.4 (1.8) <0.0001
Duration of diabetes
≥5 years % (n) 83.0 (26,724) 83.1 (2,907) 75.1 (334) <0.0001
Prior insulin
≥5 years on insulin % (n) 48.1 (15,525) 58.3 (2,046) 5.4 (24) <0.0001
Prior cancer
Ever 4.7 (1,531) 2.6 (90) 8.7 (39) 0.92
≤5 years ago 2.3 (754) 1.5 (52) 5.4 (24) 0.24
Prior CVD % (n) 12.1 (3,919) 5.6 (196) 21.5 (96) 0.014
Ever smoked % (n) 30.5 (7,553) 27.9 (812) 26.0 (89) 0.0008
Diabetes type
Type 1 % (n) 35.8 (11,547) 62.2 (2,184) 3.4 (15)b
Type 2 % (n) 57.2 (18,455) 29.4 (1,033) 92.0 (411)
Undefined type % (n) 7.1 (2,293) 8.4 (295) 4.7 (21) <0.0001
Age at diagnosis, years median 41 25 57 <0.0001
In the two most deprived SIMD quintiles % (n) 44.4 (14,351) 36.7 (1,288) 53.7 (240) <0.0001
Missing values for BMI, Systolic BP, Diastolic BP, HbA1c, Duration of diabetes and ever smoked
a Age- and sex-adjusted. Values are for tests of whether the overall variation between groups is significant and are taken from linear and logistic
regressions of continuous and binary variables, respectively
b These are likely to be type 2 misclassified as type1
LQ, Lower quartile; UQ, upper quartile
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All cancers A total of 715 incident cancers occurred in this
cohort during follow-up in 36,254 subjects (1.97%, 0.95
events per 100 person-years at risk). Among those
receiving any insulin glargine (regardless of whether
they received any other type of insulin), 1.29% had a
cancer compared with 2.06% of those on non-glargine
insulin alone. There was no overall difference in all
cancer rates in those receiving vs those not receiving
insulin glargine (HR 1.02, 95% CI 0.77–1.36, p=0.9).
For breast cancer, there was no significant difference
between insulin glargine users vs users of non-glargine
insulin alone (HR 1.49, 95% CI 0.79–2.83, p=0.22). None
of the other site-specific cancer rates were associated with
insulin glargine use.
Table 3 shows the number of cancers that occurred,
together with their cumulative incidence (%), plus the age-
and sex-adjusted HR for the fixed cohort for the three
insulin exposure categories. Compared with those using
non-glargine insulin alone, those who were using non-
glargine plus glargine insulin had a slightly, but non-
significantly, lower rate of cancer, but those using insulin
glargine alone (all of whom would have type 2 diabetes)
had a higher rate of cancer, which was of borderline
statistical significance. Adjusting for further covariates in
those on insulin glargine only made very little difference to
the HR (change from 1.55 to 1.73, most of which was due
to slight differences in the numbers available for the
models; the HR for model 1 restricted to those with
complete data for model 4 was 1.63, 95% CI 0.95–2.78,
p=0.074). Restricting the model to those without any prior
cancer only slightly altered the HRs for those on non-
glargine plus glargine insulin (0.78, 95% CI 0.53–1.16) and
those on insulin glargine alone (1.64, 95% CI 1.05–2.54).
In another model we examined the same associations
conditional upon survival for the first year (to examine
whether all the effects are early after treatment initiation
or conversely affected by a lag time) but this made no
difference (data not shown).
When the analyses were restricted to the 19,899 definite
type 2 diabetic patients there was no difference in cancer
rates between insulin glargine users (irrespective of whether
they were using any other type of insulin) vs users of non-
glargine insulin (HR 1.08, 95% CI 0.78–1.49, p=0.64 ).
When the three exposure categories were examined, a
Table 2 Baseline characteristics of the fixed cohort by insulin glargine exposure group: type 2 diabetic patients only (n=19,899)
Characteristic Data presented as Non-glargine
insulin
Non-glargine plus
glargine insulin
Insulin glargine
only
p valuea
Subjects % (n) 92.7 (18,455) 5.2 (1,033) 2.1 (411)
Sex, % women % (n) 48.8 (8,996) 48.5 (501) 52.6 (216) 0.13
Age, years Median (LQ, UQ) 65 (56,72) 57 (49, 66) 69 (59,77) <0.0001
BMI, kg/m2 Mean (SD) 30.4 (6.1) 27.9 (5.7) 30.1 (6.2) <0.0001
Systolic BP, mmHg Mean (SD) 139.3 (22.2) 136.1 (19.5) 140.5 (20.5) 0.19
Diastolic BP, mmHg Mean (SD) 76 (12) 77 (12) 77 (13) 0.006
HbA1c, % Mean (SD) 8.5 (1.7) 9.0 (1.7) 9.3 (1.8) <0.0001
Duration of diabetes
≥5 years % (n) 83.2 (15,360) 76.8 (793) 75.2 (309) <0.0001
Prior Insulin
≥5 years on insulin % (n) 37.2 (6,867) 47.1 (487) 4.6 (19) <0.0001
Age at diagnosis, years Median 53 46 59 <0.0001
Prior cancer
Ever % (n) 7.4 (1,357) 5.0 (52) 9.3 (38) 0.59
≤5 years ago % (n) 3.6 (664) 2.7 (28) 5.6 (23) 0.35
Any CVD % (n) 18.6 (3,441) 12.1 (125) 22.1 (91) 0.016
Ever smoked % (n) 29.9 (4,335) 28.4 (247) 24.8 (77) 0.001
Use of oral glucose-lowering drugs at baselineb % (n) 28.9 (4,559) 23.4 (169) 80.0 (295) <0.0001
On three or more oral glucose-lowering
drugs at baseline
% (n) 4.0 (745) 3.1 (32) 29.4 (121) <0.0001
In the two most deprived SIMD quintiles % (n) 47.1 (8,686) 35.4 (366) 54.0 (222) <0.0001
a Age- and sex-adjusted. Values are for tests of whether the overall variation between groups is significant and are taken from linear and logistic
regressions of continuous and binary variables, respectively
b Denominator for oral glucose lowering drugs excludes 3,005 (15%) of subjects for whom oral drug prescription is not known with certainty
LQ, Lower quartile; UQ, upper quartile
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pattern similar to that in the cohort as a whole was seen,
with higher rates in those using insulin glargine alone (HR
1.58, 95% CI 1.03–2.42, p=0.037) compared with those
using non-glargine insulin alone. There was no significant
effect of baseline exposure to any of the oral diabetes drugs
on cancer rate when evaluated separately, and adjusting for
these variables made no difference to the effects of insulin
glargine. When the analyses were restricted to type 1
diabetic patients, the HR for non-glargine plus glargine
insulin users was closer to, and not statistically significantly
different from, unity (HR 1.02, 95% CI 0.50–2.09, p=0.9).
Site-specific cancers Table 4 shows the HRs for site-
specific cancer associated with exposure to insulin glargine
and the effect of adjusting for covariates in the fixed cohort.
The number of cancers by site is so small that power is low.
However, 92 cases of breast cancer occurred in the women,
six of which were in insulin glargine only users. Overall,
insulin glargine use was not associated with an increased
risk of breast cancer (HR 1.49, 95% CI 0.79–2.83, p=0.2),
but as shown in Table 4, the pattern seen for all cancers
combined was replicated: there was a significantly higher
rate in insulin glargine only users compared with users of
non-glargine insulin alone. Adjustment for covariates
generally made little difference. When restricted to type 2
diabetes, the same pattern was observed. For lung and
colon cancer, a similar pattern of HRs above 1 in insulin
glargine only users and HRs below 1 in non-glargine plus
Table 3 Total cancers by insulin glargine group in the fixed cohort
Data presented as Non-glargine
insulin
Non-glargine plus
glargine insulin
Insulin glargine only
All cancers n (%) 664 (2.1) 29 (0.8) 22 (4.9)
Incidence rate per
100 person-years
1.0 0.39 2.6
Model 1a (n=36,254) HR (95% CI) Reference 0.80 (0.55–1.17) p=0.26 1.55 (1.01–2.37) p=0.045
Model 2b (n=36,254) HR (95% CI) Reference 0.80 (0.55–1.17) p=0.26 1.56 (1.00–2.45) p=0.052
Model 3c (n=28,696) HR (95% CI) Reference 0.87 (0.59–1.30) p=0.51 1.65 (1.03–2.66) p=0.038
Model 4d (n=21,813) HR (95% CI) Reference 0.88 (0.55–1.40) p=0.58 1.73 (0.98–3.05) p=0.057
aModel 1 adjusts for prior cancer, type of diabetes and calendar year, and is stratified by sex; timescale is age
bModel 2 further adjusts for metformin, sulfonylurea and other oral hypoglycaemic drugs at baseline
cModel 3 further adjusts for diabetes duration, HbA1c, diastolic BP, systolic BP and deprivation quintile
dModel 4 further adjusts for smoking ever and BMI, but note the reduction in available sample size
Table 4 Site-specific cancers by insulin glargine group in the fixed cohort
Site Data presented as Non-glargine insulin Non-glargine plus glargine insulin Insulin glargine only
Breast cancer n (%) 81 (0.5) 5 (0.3) 6 (2.6)
Model 1a (n=17,151) HR (95% CI) Reference 0.87 (0.34–2.17) p=0.76 3.39 (1.46–7.85) p=0.004
Model 2b (n=17,151) HR (95% CI) Reference 0.85 (0.34–2.14) p=0.73 3.92 (1.58–9.70) p=0.003
Model 3c (n=13,635) HR (95% CI) Reference 1.07 (0.42–2.73) p=0.88 5.04 (1.95–13.03) p=0.001
Model 4c (n=10,307) HR (95% CI) Reference 1.10 (0.38–3.16) p=0.86 3.65 (1.05–12.68) p=0.042
Prostate n (%) 44 (0.26) 3 (0.17) 1 (0.47)
Model 1a (n=19,103) HR (95% CI) Reference 1.76 (0.54–5.74) p=0.35 1.16 (0.16–8.50) p=0.88
Colorectal 104 (0.32) 2 (0.06) 3 (0.67)
Model 1a (n=36,254) HR (95% CI) Reference 0.36 (0.09–1.45) p=0.15 1.43 (0.45–4.57) p=0.54
Lung n (%) 140 (0.43) 5 (0.14) 4 (0.89)
Model 1a (n=36,254) HR (95% CI) Reference 0.47 (0.18–1.25) p=0.13 1.43 (0.53–3.88) p=0.49
Pancreatic n (%) 38 (0.12) 1 (0.03) 0
Model 1a (n=36254) HR (95% CI) Reference 0.54 (0.08–4.32) p=0.60 No events
aModel 1 adjusts for prior cancer, type of diabetes and calendar year, and is stratified by sex ; timescale is age
bModel 2 further adjusts for metformin, sulfonylurea and other oral hypoglycaemic drugs at baseline
cModel 3 further adjusts for diabetes duration, HbA1c, diastolic BP, systolic BP and deprivation quintile
dModel 4 further adjusts for smoking ever and BMI, but note the reduction in available sample size due to missing covariates
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glargine insulin users was observed, but none of the HRs
was statistically significant.
Incident cohort analysis
There were 12,852 definite type 2 diabetic patients who
received insulin for the first time between 1 January 2002
and 31 December 2005, 12,845 of which had follow-up
data. Electronic supplementary material (ESM) Table 1
shows the baseline characteristics in the three exposure
categories. The characteristics of these incident users differ
from those of the fixed cohort, and the between-group
differences in baseline characteristics are different to those
seen in the fixed cohort. Compared with those on non-
glargine insulin only, insulin glargine only users were, like
those in the fixed cohort, older and had a higher BP but,
unlike those in the fixed cohort, they had a slightly longer
duration of diabetes, similar glycaemic control and less
CVD.
A total of 378 cancers occurred in this incident cohort
(Table 5). Overall, the incidence of cancer was not different
between insulin glargine users (regardless of what other
type of insulin was used by them) vs users of non-glargine
insulin alone (HR 0.93, 95% CI 0.70–1.25, p=0.64).
Unlike in the fixed cohort analysis, the incidence rate in
insulin glargine only users was not higher than in users of
non-glargine insulin alone (HR 0.87, 95% CI 0.63–1.21,
p=0.41), and this was also the case when adjustment for
covariates was made (Table 5). Restricting the analysis to
only include patients with type 2 diabetes did not alter this
pattern. For site-specific cancers, the numbers are very
small, but show no significant difference in breast cancer
rates, although the HR is 1.47 for insulin glargine only
users vs non-glargine insulin only users. It should be noted
that the number of insulin glargine only users in this
analysis is higher than that in the fixed cohort, which is
expected given that insulin glargine use has increased since
its introduction.
Analysis summarising exposure across the entire follow-up
In the analysis in which we summarised exposure across
the entire follow-up period overall (see ESM), we included
49,197 patients who received a prescription for insulin
therapy at some point between 1 January 2002 and 31
December 2005, in whom 1,523 cancers occurred (see
ESM Tables 2, 3, 4). Overall, among those receiving any
insulin glargine (regardless of what other insulin was used
by them), there was a significantly lower rate of total
cancers (HR 0.69, 95% CI 0.60–0.79, p<0.0001) when
adjustments were made for sex, prior cancer, calendar
period and type of diabetes. When we further examined
whether the years of cumulative exposure to insulin
glargine was associated with cancer rate, this lower HR
was lowest in those with at least 2 years of exposure (HR
0.60, 95% CI 0.51–0.70). Those on non-glargine plus
glargine insulin had a significantly lower incidence rate of
cancers than those on non-glargine insulin only (HR 0.53,
95% CI 0.45–0.63), and those on insulin glargine alone had
a significantly higher incidence rate of cancer than those on
non-glargine insulin only (HR 1.28, 95% CI 1.04–1.59).
The same pattern was seen when those with prior cancer
were excluded and when the analysis was restricted to type
2 diabetes. For breast cancer, there was a slightly higher
incidence among those on insulin glargine alone compared
with those on non-glargine insulin (HR 1.33, 95% CI 0.69–
2.56); this difference was non-significant.
Discussion
In this analysis of Scotland-wide data, we found no
difference in the rate of total cancers or site-specific
cancers between those exposed to insulin glargine therapy
vs those not exposed to insulin glargine therapy. Cancer
rates were not positively associated with cumulative years
of exposure to insulin glargine therapy. Thus, our primary
hypothesis that exposure to insulin glargine was associated
Table 5 Cancers by insulin glargine group in the incident insulin users cohort: type 2 diabetic patients only
Data presented as Non-glargine
insulin
Non-glargine plus
glargine insulin
Insulin glargine only
All cancers n (%) 320 (3.1) 14 (2.0) 44 (2.3)
Incidence rate per
100 person-years
1.7 1.6 1.9
Model 1 (n=12,845a) HR (95% CI) Reference 1.20 (0.69 2.09) p=0.53 0.87 (0.63–1.21) p=0.41
Breast cancer n (%) 29 (0.61) 0 (0) 6 (0.65)
Incidence rate per
100 person-years
0.3 0.5
Model 1 (n=5,963) HR (95% CI) Reference No events 1.47 (0.59–3.64) p=0.41
a Excludes seven subjects without follow-up data
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with an adverse effect on total cancer rates or site-specific
cancer was refuted, and these data are reassuring in this
regard.
When we subdivided our exposure categories into those
who, during the observation period, used insulin glargine as
their only insulin vs those who used insulin glargine with
other insulins or used non-glargine insulin alone, a different
pattern was seen. We subdivided the categories in this way
because the analysis by Hemkens et al. [8], which reports a
concern regarding the carcinogenicity of insulin glargine,
was restricted to users of insulin glargine who were not
using any other insulins concurrently. We wanted to
understand whether restricting the analysis to such a
subgroup could lead to a biased estimate of any overall
relationship between cancer and insulin glargine, not
because we were hypothesising differential effects of
insulin glargine that are dependent on concomitant insulin.
In this analysis, those using insulin glargine as their only
insulin were found to have a higher cancer rate for all
cancers and a higher rate for breast cancer specifically,
compared with those using non-glargine plus glargine
insulin or those using non-glargine insulin alone. This was
demonstrated in the fixed cohort users but not in the
incident insulin users. A similar pattern was found for lung
and colorectal cancer, with HRs above 1 observed in insulin
glargine only users and HRs below 1 seen in those using
non-glargine plus glargine insulin. This lower rate among
the combined users was more extreme in the analysis in
which exposure was summarised across the entire follow-
up period.
As there are few events in these subgroup analyses the
observed association may reflect chance. The p values are
based on large sample approximations, and these are less
valid when events are sparse. They, nonetheless, warrant
discussion and interpretation in view of the paper by
Hemkens et al. [8]. Our analysis of baseline characteristics
shows that insulin glargine only users differ substantially
as a group from those using non-glargine plus glargine
insulin or those using non-glargine insulin alone. Even
restricting comparisons to those with type 2 diabetes, they
are clearly an older group with worse glycaemic control,
and were on more intensive oral therapy. Adjusting for
these potential confounders did little to explain, in a
statistical sense, the higher observed cancer rate for this
group. It should be noted that for past and current oral
drugs these adjustments do not fully capture all retrospec-
tive exposure with precise quantification, as this is not
possible with the dataset. In our view, the potential for
allocation bias (otherwise termed confounding by indica-
tion) here is very high, i.e. that those generally less healthy
patients were more likely to have been prescribed this
simple-to-use once daily insulin glargine regimen than
other insulins that require more frequent injections or have
a greater risk of nocturnal hypoglycaemia. Less healthy
patients might also be less likely to be prescribed
additional non-glargine insulin on top of insulin glargine.
Therefore, we cannot exclude allocation bias as the most
likely reason for observing this higher cancer rate in
insulin glargine only users and, similarly, the slightly
lower rate in those using non-glargine plus glargine
insulin. Furthermore, we cannot fully disentangle any
potential effect of insulin glargine from the other drugs
that are more commonly used in this group. It would only
be possible to conclude that the rate differences between
subgroups were likely to be real if the baseline character-
istics had been similar between exposure groups. We
performed an analysis of incident users of insulin in an
attempt to improve the comparability of the three exposure
groups, at least in terms of what might broadly be termed
stage of progression of diabetes (though, of course, there
remains variability in the timing of initiation of insulin
therapy [14]). That these subgroup effects were less
apparent in this analysis supports our interpretation that
the effects are not likely to be causal. Importantly, we
would expect that if exposure to insulin glargine were
harmful, this effect would be seen regardless of use of
other insulin. Instead, we found that there was no
increased risk associated with insulin glargine and, indeed,
in the analysis that summarises exposure across the entire
follow-up period, the opposite was observed. The short
period of time between exposure and events in these
analyses also argues strongly against a causal relationship.
Consistent with allocation bias, as described in the
introduction, the clinical guidelines operant in Scotland
during this period have encouraged limiting insulin
glargine use in type 2 diabetes to those requiring
assistance with insulin or with problems of nocturnal
hypoglycaemia. Whilst the data show that clinicians in
Scotland are actually prescribing insulin glargine to a
much wider range of patients than this it is also clear that
such patients will be over-represented in the insulin
glargine only group.
Another limitation of our analysis is that we do not yet
have data available on drug dose; thus, we were not able to
test the hypothesis that higher doses of any insulin are
associated with higher cancer rates or whether the slope of
such a relationship varies by insulin type. A third important
methodological aspect of this observational analysis is that
the use of other drugs varies substantially by insulin
glargine exposure status. As shown, those using insulin
glargine without any other insulin have, not surprisingly, a
much higher rate of current use of oral glucose-lowering
drugs. Once again, adjusting for use of these drugs had little
effect on the risk ratios observed for insulin glargine use,
but the possibility of residual confounding through other
drug effects remains, and we have not fully captured
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cumulative exposure in the past to other drugs, which may
be relevant [15].
One of the limitations of our analysis is that we only had
cancer registry data through to the end of 2005, with first
insulin glargine exposure occurring in 2002. Therefore,
follow-up time was short for evaluating cancer effects.
Another aspect is that our linkage for this current study
does not contain people with diabetes who are not on any
insulin. A fuller analysis of cancer rates across all diabetic
patients and their therapeutic subgroups compared with the
general population is what is warranted, and this will now
be carried out.
So where does this leave the concern about the
mitogenicity of insulin glargine? The concern arises from
the fact that modifications to the structure of the insulin
molecule can alter binding to the insulin IGF receptors,
theoretically altering carcinogenicity. Data from cell and
animal model studies are conflicting [16–21]. In contrast to
these numerous studies in cell and animal models, powerful
studies of cancer effects in humans using insulin glargine
are lacking. Systematic reviews of the effects of insulin
analogues on glycaemic outcomes have pointed to a lack of
trials of sufficient duration to evaluate cancer rates (or,
indeed, even beneficial effects on hard clinical outcomes of
complications rates) [6], and have concluded that more
studies are needed to better understand the effect of insulin
analogues on long-term diabetes complications and the
safety of these agents [7]. As this analysis of our large
dataset also highlights, observational analysis of drug
effects is not a substitute for randomised trials because,
fundamentally, one can never completely rule out allocation
bias except by random allocation. Observational analyses
can raise hypotheses about harm and in many cases they
can provide reassurance about harm. Whilst our data do not
provide complete reassurance about cancer rates and insulin
glargine use, neither do they point to unequivocal evidence
of harm. Had we found evidence of increased cancer rates
among all categories of insulin glargine use we would have
been much more concerned, and, conversely, lower rates
among all categories of use would have been more
reassuring. Nonetheless, what this emphasises is that
continuing controversy over potential carcinogenic con-
cerns can probably only be addressed by randomised trial
data. Where there is equipoise about beneficial effects of
new drugs, as the systematic reviews of the effectiveness
of insulin analogues demonstrate, then clear demonstration
of lack of harm should become even more critical to clinical
decision making. In the meantime, clinicians should inform
patients being prescribed insulin glargine about the relative
lack of safety information for newer insulins when con-
sidering whether potential benefits with regard to ease of
administration or management of nocturnal hypoglycaemia
are worthwhile.
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